Search

Your search keyword '"Addeo P"' showing total 762 results
Start Over Author "Addeo P"
762 results on '"Addeo P"'

2. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study

Author

Addeo, Pietro, Muzzolini, Milena, Laurent, Christophe, Heyd, Bruno, Sauvanet, Alain, Garnier, Jonathan, Alfano, Marie Sophie, Gaujoux, Sebastien, De Ponthaud, Charles, Marchese, Ugo, Da Silva, Doris, Buc, Emmanuel, Souche, Regis, Fabre, Jean Michel, Colombo, Pierre-Emanuel, Ferre, Lorenzo, Foguenne, Maxime, Hubert, Catherine, El Amrani, Mehdi, Truant, Stephanie, Schwartz, Lilian, Regenet, Nicolas, Dupre, Aurelien, Brustia, Raffaele, Cherif, Rim, Navez, Julie, Darnis, Benjamin, Facy, Olivier, Grellet, Robin, Piessen, Guillaume, Veziant, Julie, Rhaiem, Rami, Kianmanesh, Reza, Fernandez-De-Sevilla, Elena, Gelli, Maximiliano, Taibi, Abdelkader, Georges, Pauline, Mabrut, Jean Yves, Lesurtel, Mickael, Doussot, Alexandre, and Bachellier, Philippe

Published
2025
Full Text
View/download PDF

4. Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors

Author

Mamulashvili Bessac, Darejan, Baltzinger, Philippe, Poterszman, Nathan, Pham Van, Floriane, Collen, Cedric, Malouf, Gabriel G., Ouvrard, Eric, Kaseb, Ashjan, Porot, Clemence, Ben Abdelghani, Meher, Addeo, Pietro, Mertz, Luc, Goichot, Bernard, and Imperiale, Alessio

Published
2024
Full Text
View/download PDF

6. ASO Author Reflections: Complete Pathological Response after Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinomas—Curative Surgery in Cured Patients?

Author

Addeo, Pietro, Muzzolini, Milena, Laurent, Christophe, Heyd, Bruno, Sauvanet, Alain, Garnier, Jonathan, Alfano, Marie Sophie, Gaujoux, Sebastien, De Ponthaud, Charles, Marchese, Ugo, Da Silva, Doris, Buc, Emmanuel, Souche, Regis, Fabre, Jean Michel, Colombo, Pierre-Emanuel, Ferre, Lorenzo, Foguenne, Maxime, Hubert, Catherine, El Amrani, Mehdi, Truant, Stephanie, Schwartz, Lilian, Regenet, Nicolas, Dupre, Aurelien, Brustia, Raffaele, Cherif, Rim, Navez, Julie, Darnis, Benjamin, Facy, Olivier, Grellet, Robin, Piessen, Guillaume, Veziant, Julie, Rhaiem, Rami, Kianmanesh, Reza, Fernandez-De-Sevilla, Elena, Gelli, Maximiliano, Taibi, Abdelkader, Georges, Pauline, Mabrut, Jean Yves, Lesurtel, Mickael, Doussot, Alexandre, and Bachellier, Philippe

Published
2025
Full Text
View/download PDF

9. Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation

Author

Grisolia, Piera, Tufano, Rossella, Iannarone, Clara, De Falco, Antonio, Carlino, Francesca, Graziano, Cinzia, Addeo, Raffaele, Scrima, Marianna, Caraglia, Francesco, Ceccarelli, Anna, Nuzzo, Pier Vitale, Cossu, Alessia Maria, Forte, Stefano, Giuffrida, Raffaella, Orditura, Michele, Caraglia, Michele, and Ceccarelli, Michele

Published
2024
Full Text
View/download PDF

10. Identification and bioinformatic characterization of a serum miRNA signature for early detection of laryngeal squamous cell carcinoma

Author

Falco, Michela, Tammaro, Chiara, Cossu, Alessia Maria, Takeuchi, Takashi, Tufano, Rossella, Ceccarelli, Michele, Scafuro, Giuseppe, Zappavigna, Silvia, Grimaldi, Anna, Scrima, Marianna, Ottaiano, Alessandro, Savarese, Giovanni, Fico, Antonio, Mesolella, Massimo, Fasano, Morena, Motta, Giovanni, Massimilla, Eva Aurora, Addeo, Raffaele, Ricciardiello, Filippo, Caraglia, Michele, and Misso, Gabriella

Published
2024
Full Text
View/download PDF

11. Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer

Author

Bocchetti, Marco, Luce, Amalia, Iannarone, Clara, Pasquale, Lucia Stefania, Falco, Michela, Tammaro, Chiara, Abate, Marianna, Ferraro, Maria Grazia, Addeo, Raffaele, Ricciardiello, Filippo, Motta, Giovanni, De Stefano, Luca, Caraglia, Francesco, Ceccarelli, Anna, Zappavigna, Silvia, Scrima, Marianna, Cossu, Alessia Maria, Caraglia, Michele, and Misso, Gabriella

Published
2024
Full Text
View/download PDF

14. ASO Visual Abstract: Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for Pancreatic AdenOcarciNOma in the FOFLIRINOX Era: The Multicenter TONO Study

Author

Addeo, Pietro, Muzzolini, Milena, Laurent, Christophe, Heyd, Bruno, Sauvanet, Alain, Garnier, Jonathan, Alfano, Marie Sophie, Gaujoux, Sebastien, De Ponthaud, Charles, Marchese, Ugo, Da Silva, Doris, Buc, Emmanuel, Souche, Regis, Fabre, Jean Michel, Colombo, Pierre-Emanuel, Ferre, Lorenzo, Foguenne, Maxime, Hubert, Catherine, Amrani, Mehdi El, Truant, Stephanie, Schwartz, Lilian, Regenet, Nicolas, Dupre, Aurelien, Brustia, Raffaele, Cherif, Rim, Navez, Julie, Darnis, Benjamin, Facy, Olivier, Grellet, Robin, Piessen, Guillaume, Veziant, Julie, Rhaiem, Rami, Kianmanesh, Reza, Fernandez-De-Sevilla, Elena, Gelli, Maximiliano, Thaibi, Abdelkader, Georges, Pauline, Mabrut, Jean Yves, Lesurtel, Mickael, Doussot, Alexandre, and Bachellier, Philippe

Published
2025
Full Text
View/download PDF

23. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

Author

El Zarif, Talal, Nassar, Amin, Adib, Elio, Fitzgerald, Bailey, Huang, Jiaming, Mouhieddine, Tarek, Rubinstein, Paul, Nonato, Taylor, McKay, Rana, Li, Mingjia, Mittra, Arjun, Owen, Dwight, Baiocchi, Robert, Lorentsen, Michael, Dittus, Christopher, Dizman, Nazli, Falohun, Adewunmi, Abdel-Wahab, Noha, Diab, Adi, Bankapur, Anand, Reed, Alexandra, Kim, Chul, Arora, Aakriti, Shah, Neil, El-Am, Edward, Kozaily, Elie, Abdallah, Wassim, Al-Hader, Ahmad, Abu Ghazal, Batool, Saeed, Anwaar, Drolen, Claire, Lechner, Melissa, Drakaki, Alexandra, Baena, Javier, Nebhan, Caroline, Haykal, Tarek, Morse, Michael, Cortellini, Alessio, Pinato, David, Dalla Pria, Alessia, Hall, Evan, Bakalov, Veli, Bahary, Nathan, Rajkumar, Aarthi, Mangla, Ankit, Shah, Vishal, Singh, Parminder, Aboubakar Nana, Frank, Lopetegui-Lia, Nerea, Dima, Danai, Dobbs, Ryan, Funchain, Pauline, Saleem, Rabia, Woodford, Rachel, Long, Georgina, Menzies, Alexander, Genova, Carlo, Barletta, Giulia, Puri, Sonam, Florou, Vaia, Idossa, Dame, Saponara, Maristella, Queirolo, Paola, Lamberti, Giuseppe, Addeo, Alfredo, Bersanelli, Melissa, Freeman, Dory, Xie, Wanling, Reid, Erin, Chiao, Elizabeth, Sharon, Elad, Johnson, Douglas, Ramaswami, Ramya, Bower, Mark, Emu, Brinda, Marron, Thomas, Choueiri, Toni, Baden, Lindsey, Lurain, Kathryn, Sonpavde, Guru, and Naqash, Abdul

Subjects
Male, Humans, Middle Aged, Female, Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck, Liver Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Head and Neck Neoplasms, HIV Infections
Abstract

PURPOSE: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS: This retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS: Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load

Published
2023

24. Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022.

Author

Olivier, Timothée, Smith, Claire EP, Haslam, Alyson, Addeo, Alfredo, and Prasad, Vinay

Subjects
Adjuvant, Clinical trials, Health Policy, Health related quality of life, Oncology, Quality of life, Rare Diseases, Cancer, Clinical Trials and Supportive Activities, Clinical Research
Abstract

BackgroundIn oncology, quality of life (QoL) questionnaires were historically designed to be used in the advanced or metastatic setting. We sought to determine the effects of contemporary treatments on QoL in the adjuvant setting and to determine if the QoL instruments used in these studies provide a relevant assessment.MethodsWe conducted a systematic identification of all anti-cancer drugs used in the adjuvant setting and approved by the US Food and Drug Administration from January 2018 to March 2022. We conducted a quality evaluation and a meta-analysis of reported QoL results. We used the global QoL results when multiple QoL outcomes were reported.ResultsThere were 224 FDA approvals reviewed, of which 12 met the inclusion criteria. The placebo was the control arm in 10 out of 12 trials. Of those, 11 trials (92 %) assessed QoL, and ten (83 %) reported results. In reports with QoL results, a moderate-risk of bias was found in 3 out of 10 (30 %) and a high-risk of bias in 6 out of 10 (60 %) of reports, respectively. No trial reported a meaningful difference between arms. The meta-analysis found an overall detrimental effect on QoL in the experimental arm, though it was not statistically different.ConclusionThis study identified 12 FDA registration trials in the adjuvant setting between 2018 and 2022. We found a moderate- to high-risk of bias in 90 % of the ten trials reporting QoL data. Our meta-analysis suggested a detrimental effect on QoL in the experimental arm, questioning the relevancy, in the adjuvant setting, of thresholds that were mostly developed in the advanced or metastatic setting.Policy summaryFuture works should focus on specificities of the adjuvant setting when considering QoL evaluation.

Published
2023

41. Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.

Author

Torgersen, Jessie, Kallan, Michael J, Carbonari, Dena M, Park, Lesley S, Mehta, Rajni L, D'Addeo, Kathryn, Tate, Janet P, Lim, Joseph K, Goetz, Matthew Bidwell, Rodriguez-Barradas, Maria C, Bräu, Norbert, Brown, Sheldon T, Taddei, Tamar H, Justice, Amy C, and Lo Re, Vincent

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Liver Cancer, HIV/AIDS, Rare Diseases, Chronic Liver Disease and Cirrhosis, Prevention, Cancer, Liver Disease, Digestive Diseases, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Age Factors, Alanine Transaminase, Aspartate Aminotransferases, Carcinoma, Hepatocellular, Clinical Decision Rules, Cross-Sectional Studies, Female, HIV Infections, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Platelet Count, Registries, Virginia, FIB-4, cirrhosis, HIV, hepatocellular carcinoma, Clinical Sciences, Public Health and Health Services, Virology, Clinical sciences, Epidemiology, Public health
Abstract

BackgroundHepatocellular carcinoma (HCC) may develop in the absence of cirrhosis in HIV, and determining how often this occurs can provide insights into mechanisms of carcinogenesis. Studies evaluating the prevalence of cirrhosis in the setting of HCC among people living with HIV (PLWH) often rely on noninvasive markers, such as the Fibrosis-4 Index for Hepatic Fibrosis (FIB-4). However, the accuracy of FIB-4 for cirrhosis in the setting of HCC has not been determined among PLWH.MethodsWe conducted a cross-sectional study among PLWH in the Veterans Aging Cohort Study with VA cancer registry-confirmed HCC diagnosed between 1999 and 2015. FIB-4 was calculated using the age, alanine aminotransferase, aspartate aminotransferase, and platelet count obtained closest to, but within 1 year before, HCC diagnosis. Medical records were reviewed within 1 year before HCC diagnosis to determine the cirrhosis status. We evaluated the area under the receiver-operating characteristic curve and performance characteristics of FIB-4 for confirmed cirrhosis.ResultsIncident HCC was diagnosed in 302 PLWH. After medical record review, 203 (67.2%, 95% confidence interval: 61.6% to 72.5%) had evidence of cirrhosis. FIB-4 identified patients with cirrhosis with an area under the receiver-operating characteristic curve of 0.67 (95% confidence interval: 0.60 to 0.73). FIB-4 scores >5.0 had a positive predictive value >80% and specificity of >77%, negative predictive value of

Published
2020

43. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status.

Author

Torgersen, Jessie, Kallan, Michael J, Carbonari, Dena M, Park, Lesley S, Mehta, Rajni L, D’Addeo, Kathryn, Tate, Janet P, Lim, Joseph K, Goetz, Matthew Bidwell, Rodriguez-Barradas, Maria C, Gibert, Cynthia L, Bräu, Norbert, Brown, Sheldon T, Roy, Jason A, Taddei, Tamar H, Justice, Amy C, and Lo Re, Vincent

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Digestive Diseases, Cancer, Prevention, Hepatitis, Infectious Diseases, Rare Diseases, Chronic Liver Disease and Cirrhosis, Clinical Research, HIV/AIDS, Liver Disease, Liver Cancer, Infection, Good Health and Well Being, Adult, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Carcinoma, Hepatocellular, Cohort Studies, Female, HIV, HIV Infections, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, RNA, Viral, Retrospective Studies, United States, United States Department of Veterans Affairs, Veterans, Viremia, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundDespite increasing incidence of hepatocellular carcinoma (HCC) among HIV-infected patients, it remains unclear if HIV-related factors contribute to development of HCC. We examined if higher or prolonged HIV viremia and lower CD4+ cell percentage were associated with HCC.MethodsWe conducted a cohort study of HIV-infected individuals who had HIV RNA, CD4+, and CD8+ cell counts and percentages assessed in the Veterans Aging Cohort Study (1999-2015). HCC was ascertained using Veterans Health Administration cancer registries and electronic records. Cox regression was used to determine hazard ratios (HR, 95% confidence interval [CI]) of HCC associated with higher current HIV RNA, longer duration of detectable HIV viremia (≥500 copies/mL), and current CD4+ cell percentage less than 14%, adjusting for traditional HCC risk factors. Analyses were stratified by previously validated diagnoses of cirrhosis prior to start of follow-up.ResultsAmong 35 659 HIV-infected patients, 302 (0.8%) developed HCC over 281 441 person-years (incidence rate = 107.3 per 100 000 person-years). Among patients without baseline cirrhosis, higher HIV RNA (HR = 1.25, 95% CI = 1.12 to 1.40, per 1.0 log10 copies/mL) and 12 or more months of detectable HIV (HR = 1.47, 95% CI = 1.02 to 2.11) were independently associated with higher risk of HCC. CD4+ percentage less than 14% was not associated with HCC in any model. Hepatitis C coinfection was a statistically significant predictor of HCC regardless of baseline cirrhosis status.ConclusionAmong HIV-infected patients without baseline cirrhosis, higher HIV RNA and longer duration of HIV viremia increased risk of HCC, independent of traditional HCC risk factors. This is the strongest evidence to date that HIV viremia contributes to risk of HCC in this group.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results